YMAB Y-mAbs Therapeutics Inc: Margin dodolan resik

Tandha merek ymabs.com (YMAB)

The loyalty of Y-mAbs Therapeutics (YMAB) scientists is based on a drive to defeat childhood cancer, yet the net profit per unit of revenue demonstrates the volatility of these processes. The value of -26.00 reflects the latest metric value. Stability is guaranteed by insurance coverage for critical pathologies regardless of crises, while the absence of therapeutic analogs allows the company to exercise significant pricing power to set the highest possible treatment costs.

Margin dodolan perusahaan ymabs.com (YMAB): kanggo periode 04.07.2022 - 27.09.2025

YmAbs - rincian analitis lan metrik utama (YMAB)

- rega saham lan prakiraan rega para ahli:
Ringkesan analitik perusahaan:Y-mAbs Corp - YMAB
Produk dadi Y-mAbs Therapeutics Inc

Holding exclusive patent rights for rare oncology treatments, Y-mAbs Therapeutics (YMAB) is shielded from generic competition, which directly impacts monetization efficiency. An analysis of the net profit margin chart allows for an assessment of the profit share per dollar of revenue, revealing the business's actual resilience and the company's financial cushion even under pessimistic market scenarios.

Analisis perusahaan pesaing

ONC: Margin dodolan resik|Margin resik Halozyme Inc. (HALO)|Margin resik RevMed|Rentabilitas dodolan resik AAPG (Ascentage Pharma Group)|Margin dodolan resik CGON|UroGen Pharma - Rentabilitas dodolan resik|Bicara Therapeutics - Rentabilitas dodolan miturut bathi resik|Margin dodolan resik Personalis Inc PSNL|Erasca Oncology - Margin dodolan resik|Tingkat bathi resik DCTH (Delcath Corp)|aurabiosciences.com (AURA) - Margin resik|Candel Therapeutics Inc. - Tingkat bathi resik|Margin resik Accuray Inc.|Margin resik SELLAS Life Sciences Group SLS|Margin dodolan resik ACTU|CTOR - Margin resik|Margin dodolan resik HURA (TuHURA Biosciences, Inc.)|Tingkat bathi resik TARA|FATE: Rentabilitas dodolan miturut bathi resik|WHWK (aadibio.com) - Rentabilitas dodolan resik|TCRX (TScan Therapeutics, Inc.) - Rentabilitas dodolan miturut bathi resik|Margin resik Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Margin dodolan resik|CVM (CEL-SCI Corporation) - Rentabilitas resik perusahaan|Margin dodolan resik OSTX|Margin dodolan resik Radiopharm Theranostics Ltd (RADX)|Margin dodolan resik ARTV (Artiva Biotherapeutics)|Margin dodolan resik Adlai Nortye Ltd. ANL|Veru Inc - Margin dodolan resik|Margin dodolan perusahaan Tempest Therapeutics TPST|XLO: Margin dodolan resik|Enochian BioSciences (RENB) - Margin dodolan resik|Rentabilitas dodolan miturut bathi resik MURA|Kairos Pharma Ltd - Margin bathi resik|Margin dodolan resik OKUR|CytoMed Therapeutics Limited (GDTC) - Tingkat bathi miturut bathi resik|Margin dodolan resik CRIS (Curis, Inc.)|APLM: Rentabilitas dodolan resik|Tharimmune Corporation - Margin dodolan resik|ADVB: Margin resik|GNPX: Margin dodolan resik|CLDI (Calidi Biotherapeutics Inc.) - Margin resik|Margin resik Sunshine Biopharma, Inc.|Margin dodolan resik xeneticbio.com|Margin resik Salarius (SLRX)|Rentabilitas dodolan miturut bathi resik Purple Biotech PPBT|Margin resik American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Margin resik|Checkpoint Therapeutics Inc. - Margin dodolan resik|Tingkat bathi resik ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Rentabilitas dodolan miturut bathi resik|Ikena Oncology, Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik NTBL|VIRX: Tingkat bathi resik|Margin resik MorphoSys Corporation (MOR)|NAYA - Margin resik|Margin dodolan resik AAPGV (Ascentage)